RPRX
Royalty Pharma plc
$54.86
-1.81%
$32.0B
No data for this timeframe.
Vol
Market Cap$32.0B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (88%)
Insider Activity0B / 12S
Insider Net $-$20.4M
SEC Reports8
Press Releases4
Recent Activity
Aug 25, 2026
fda_pdufa
PDUFA: RPRX — Ziihera in HER2-positive metastatic gastroesophageal adenocarcinoma — 2026-08-25
FDA target action date 2026-08-25 for RPRX (Royalty Pharma plc). Drug: Ziihera. Indication: HER2-pos
Jun 5, 2026
Insider
WEATHERMAN ELIZABETH H sold 4,545 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
Norden Gregory sold 4,545 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
HODGSON DAVID C sold 4,545 shares
Director @ $0.00 ($0.00)
May 28, 2026
SEC
Two senior executives at Royalty Pharma sold a combined $4.2M in open-market sales over a 7-day window, including the CF
CLUSTER — Impact 4/10
May 28, 2026
SEC
Royalty Pharma entered into a new $1.8B unsecured revolving credit facility on May 22, 2026, replacing its prior credit
8-K — Impact 4/10
May 22, 2026
SEC
Two insiders at Royalty Pharma sold a combined $883K in open-market transactions over a one-week window. The sales repre
CLUSTER — Impact 2/10
Apr 17, 2026
Press
Royalty Pharma announced a quarterly dividend of $0.235 per share, payable June 10, 2026, to shareholders of record as o
Impact 3/10
Price Targets
$59.25
+6.5% upside
Buy
Current $55.63
Low $46.00
Median $60.00
High $66.00
8 analysts
$46.00
$66.00
Analyst Ratings
5Strong Buy
9Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 7, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| May 7, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Apr 21, 2026 | UBS | MAINTAIN | Buy → Buy |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| Jan 30, 2026 | UBS | UPGRADE | Neutral → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.27 | $1.26 — $1.30 | 12% YoY | 6 |
| Next Q | $1.13 ▼ -5.6% | $1.05 — $1.21 | -4% YoY | 5 |
| Current FY | $5.12 | $4.62 — $5.33 | 6% YoY | 7 |
| Next FY | $5.61 ▲ +1.5% | $5.19 — $5.91 | 10% YoY | 7 |
Latest Reports
NEUTRAL
CLUSTER
4/10
Two senior executives at Royalty Pharma sold a combined $4.2M in open-market sales over a 7-day window, including the CF
May 28, 2026
NEUTRAL
8-K
4/10
Royalty Pharma entered into a new $1.8B unsecured revolving credit facility on May 22, 2026, replacing its prior credit
May 28, 2026
NEUTRAL
Press
3/10
Royalty Pharma announced a quarterly dividend of $0.235 per share, payable June 10, 2026, to shareholders of record as o
Apr 17, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | WEATHERMAN ELIZABETH | A | $0.00 |
| Jun 5, 2026 | Norden Gregory | A | $0.00 |
| Jun 5, 2026 | HODGSON DAVID | A | $0.00 |
| Jun 5, 2026 | LOVE TED | A | $0.00 |
| Jun 5, 2026 | Ho Carole | A | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
12 unique insiders with 12 transactions. Net insider value: -$20.4M ($0.00 bought, $20.4M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | WEATHERMAN ELIZABETH H | Director | A | 4,545 | $0.00 | $0.00 |
| Jun 5, 2026 | Norden Gregory | Director | A | 4,545 | $0.00 | $0.00 |
| Jun 5, 2026 | HODGSON DAVID C | Director | A | 4,545 | $0.00 | $0.00 |
| Jun 5, 2026 | LOVE TED W | Director | A | 4,545 | $0.00 | $0.00 |
| Jun 5, 2026 | Ho Carole | Director | A | 4,545 | $0.00 | $0.00 |
| Jun 5, 2026 | Engelbert Catherine M. | Director | A | 4,545 | $0.00 | $0.00 |
| Jun 5, 2026 | Coric Vlad | Director | A | 4,545 | $0.00 | $0.00 |
| May 26, 2026 | Coyne Terrance P. | EVP & CFO | SELL | 64,399 | $53.98 | $3.5M |
| May 20, 2026 | Urist Marshall | EVP, Research & Investments | SELL | 13,684 | $52.75 | $721.8K |
| May 14, 2026 | Norden Gregory | Director | SELL | 3,045 | $53.00 | $161.4K |
| May 14, 2026 | Urist Marshall | EVP, Research & Investments | SELL | 13,684 | $53.06 | $726.1K |
| May 6, 2026 | Legorreta Pablo G. | CEO, Chairman of the Board | A | 143,821 | $0.00 | $0.00 |
| May 6, 2026 | Coyne Terrance P. | EVP & CFO | A | 24,263 | $0.00 | $0.00 |
| May 6, 2026 | Hite Christopher | EVP & Vice Chairman | A | 24,263 | $0.00 | $0.00 |
| May 6, 2026 | Urist Marshall | EVP, Research & Investments | A | 18,197 | $0.00 | $0.00 |
| Apr 28, 2026 | Coyne Terrance P. | EVP & CFO | SELL | 32,916 | $49.78 | $1.6M |
| Apr 1, 2026 | Coyne Terrance P. | EVP & CFO | SELL | 1,875 | $48.33 | $90.6K |
| Mar 31, 2026 | Bassler Bonnie L | Director | A | 815 | $45.98 | $37.5K |
| Mar 23, 2026 | Coyne Terrance P. | EVP & CFO | SELL | 32,916 | $45.53 | $1.5M |
| Feb 23, 2026 | Coyne Terrance P. | EVP & CFO | SELL | 32,916 | $45.32 | $1.5M |
| Feb 11, 2026 | Legorreta Pablo G. | CEO, Chairman of the Board | A | 157,828 | $0.00 | $0.00 |
| Feb 11, 2026 | Coyne Terrance P. | EVP & CFO | A | 26,626 | $0.00 | $0.00 |
| Feb 11, 2026 | Hite Christopher | EVP & Vice Chairman | A | 26,626 | $0.00 | $0.00 |
| Feb 11, 2026 | Urist Marshall | EVP, Research & Investments | A | 19,970 | $0.00 | $0.00 |
| Feb 4, 2026 | Coyne Terrance P. | EVP & CFO | SELL | 19,076 | $43.29 | $825.9K |
| Feb 3, 2026 | Coyne Terrance P. | EVP & CFO | SELL | 108,759 | $42.84 | $4.7M |
| Feb 2, 2026 | Coyne Terrance P. | EVP & CFO | SELL | 102,581 | $42.08 | $4.3M |
| Jan 30, 2026 | Urist Marshall | EVP, Research & Investments | SELL | 20,000 | $41.09 | $821.8K |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 7 neutral. Avg impact: 3.3/10.
NEUTRAL
CLUSTER
4/10
Two senior executives at Royalty Pharma sold a combined $4.2M in open-market sales over a 7-day wind
May 28, 2026
NEUTRAL
8-K
4/10
Royalty Pharma entered into a new $1.8B unsecured revolving credit facility on May 22, 2026, replaci
May 28, 2026
NEUTRAL
CLUSTER
2/10
Two insiders at Royalty Pharma sold a combined $883K in open-market transactions over a one-week win
May 22, 2026
NEUTRAL
CLUSTER
3/10
Two insiders at Royalty Pharma sold a combined $888K in open-market sales on May 14, 2026, following
May 15, 2026
NEUTRAL
144
2/10
Gregory Norden, an officer of Royalty Pharma, filed a Form 144 on May 14, 2026, indicating intent to
May 14, 2026
BULLISH
8-K
6/10
Royalty Pharma reported Q1 2026 Portfolio Receipts of $925M (+10% YoY) and Royalty Receipts of $887M
May 6, 2026
NEUTRAL
PRESS-RELEASE
3/10
Royalty Pharma announced it will report Q1 2026 financial results on May 6, 2026, with no financials
Apr 15, 2026
NEUTRAL
DEFA14A
2/10
Royalty Pharma plc has filed a definitive proxy statement (DEFA14A) for an upcoming shareholder meet
Apr 10, 2026
NEUTRAL
3/10
Royalty Pharma announced a quarterly dividend of $0.235 per share, payable June 10, 2026, to shareho
Apr 17, 2026
NEUTRAL
4/10
Royalty Pharma announced a $500 million R&D co-funding agreement with Johnson & Johnson to advance J
Mar 30, 2026
NEUTRAL
3/10
Royalty Pharma announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, e
Mar 2, 2026
NEUTRAL
5/10
Royalty Pharma is providing $250 million in non-dilutive, royalty-backed financing to Zymeworks, sec
Mar 2, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 16 analysts: 5 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$59.25 mean target
+6.5% upside
Buy (1.50)
$46.00 Low
$66.00 High
| Metric | Value |
|---|---|
| Current Price | $55.63 |
| Target Low | $46.00 |
| Target Mean | $59.25 |
| Target Median | $60.00 |
| Target High | $66.00 |
| # Analysts | 8 |
| Recommendation | Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.27 | $1.26 | $1.30 | 11.8% | -0.2% | 1↑ 1↓ | $0.8B | 10.7% | 6 |
| Next Q 2026-09-30 |
$1.13 | $1.05 | $1.21 | -3.7% | -5.6% | 1↑ 1↓ | $0.9B | 7.2% | 5 |
| Current FY 2026-12-31 |
$5.12 | $4.62 | $5.33 | 6.0% | +0.3% | 4↑ 1↓ | $3.4B | 5.4% | 7 |
| Next FY 2027-12-31 |
$5.61 | $5.19 | $5.91 | 9.7% | +1.5% | 5↑ 0↓ | $3.7B | 6.7% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.275 | |
| 7d ago | $1.275 | |
| 30d ago | $1.278 | -0.003 |
| 60d ago | $1.281 | -0.006 |
| 90d ago | $1.281 | -0.006 |
4 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 7, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| May 7, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Apr 21, 2026 | UBS | MAINTAIN | Buy | Buy |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Jan 30, 2026 | UBS | UPGRADE | Neutral | Buy |
| Jan 27, 2026 | Citigroup | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| Feb 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Aug 25, 2026
fda_pdufa
PDUFA: RPRX — Ziihera in HER2-positive metastatic gastroesophageal adenocarcinoma — 2026-08-25
FDA target action date 2026-08-25 for RPRX (Royalty Pharma plc). Drug: Ziihera. Indication: HER2-positive metastatic gastroesophageal adenocarcinoma.
Jun 4, 2026
other
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
<p>NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the
Jun 1, 2026
short_volume
Short Volume: RPRX — 55.6% short (0.7M / 1.2M)
Short: 656,149 | Exempt: 1,721 | TRF Vol: 1,179,821 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: RPRX — 57.8% short (1.3M / 2.2M)
Short: 1,286,959 | Exempt: 212 | TRF Vol: 2,226,183 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: RPRX — 57.1% short (1.0M / 1.7M)
Short: 986,035 | Exempt: 0 | TRF Vol: 1,727,534 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: RPRX — 4.9M shares, 78,124 trades
Week starting 2026-05-18. Total ATS volume: 4,907,475 shares across 78,124 trades.
May 11, 2026
dark_pool
Dark Pool: RPRX — 5.0M shares, 79,492 trades
Week starting 2026-05-11. Total ATS volume: 5,019,041 shares across 79,492 trades.
May 7, 2026
other
Royalty Pharma to present at upcoming investor conferences
<p>NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming i
May 6, 2026
earnings
Royalty Pharma reports first quarter 2026 results
<p>NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2026 and r
May 6, 2026
earnings_calendar
RPRX Q1 2026 Earnings Scheduled — 2026-05-06
May 4, 2026
dark_pool
Dark Pool: RPRX — 4.6M shares, 82,995 trades
Week starting 2026-05-04. Total ATS volume: 4,611,584 shares across 82,995 trades.
Apr 27, 2026
dark_pool
Dark Pool: RPRX — 4.4M shares, 70,591 trades
Week starting 2026-04-27. Total ATS volume: 4,391,175 shares across 70,591 trades.
Apr 22, 2026
short_volume
Short Volume: RPRX — 68.1% short (0.7M / 1.0M)
Short: 650,945 | Exempt: 0 | TRF Vol: 956,030 | Short Ratio: 68.1% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
other
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
<p align="left">NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Tran
Apr 20, 2026
dark_pool
Dark Pool: RPRX — 3.1M shares, 54,752 trades
Week starting 2026-04-20. Total ATS volume: 3,067,416 shares across 54,752 trades.